The CHMP recommendations will now be forwarded to the European Commission, which will issue a final legally-binding decision.
Methysergide (DeserilĀ®) is no longer available in the UK; it was discontinued by the manufacturer in 2013 as the manufacturing site was closed and there were difficulties locating another site that could manufacture it to the required specification. DeserilĀ® was licensed for the prophylactic treatment of migraine, cluster headaches and other vascular headaches, and also for the treatment of diarrhoea caused by carcinoid disease.